Phase 4 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a serious immune condition called HLH (haemophagocytic lymphohistiocytosis), based on a specific set of recognised diagnostic guidelines (HLH-04 criteria)
- People with HLH who have confirmed or strongly suspected B-cell lymphoma (a type of blood cancer), or whose bone marrow test results show an elevated level of a specific type of immune cell (CD20-positive B cells)
- People aged 14 to 80 years old, of any sex
- People whose doctors expect them to survive for more than one month
- People whose kidney function and a blood-clotting protein (fibrinogen) meet specific laboratory thresholds, as determined by blood tests
- People who test negative for HIV, and who meet specific requirements related to hepatitis B and C infection status based on blood tests
- People whose heart pumping function (measured by an ultrasound of the heart) is at or above 50%
- People who do not have a serious, uncontrolled infection such as a lung infection, gut infection, or bloodstream infection
- Women of childbearing age who are confirmed not to be pregnant and who are willing to use effective contraception throughout the study and for at least 12 months after the last dose; pregnant or breastfeeding women are not eligible
- Male participants who are willing to use contraception throughout the trial and for at least 3 months after the last dose
- People who are able to read and sign a consent form agreeing to take part
Who may not be able to join:
- People with a known severe allergic reaction to rituximab, zanubrutinib, or similar medications (BTK inhibitors)
- People with a severe active infection (bacterial, viral, or fungal) that is not under control
- People with serious organ problems, such as advanced heart failure or severe irregular heart rhythms, significantly elevated liver enzymes or severe liver scarring, or severely reduced kidney function
- People who also have another cancer where life expectancy is less than 3 months
- People who are currently taking part in another clinical trial and have not yet completed the required period of time after stopping that trial's medication
- Women who are pregnant or breastfeeding, or anyone unwilling to use effective contraception as required
- People who, in the treating doctor's judgement, have any other condition that could make participation unsuitable, affect their ability to follow the study requirements, or raise safety concerns
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xuefeng He, doctor, department of hematology, The First Affiliated Hospital of Soochow University
Phone: 86-18914031640
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
response rate of HLH after 4 weeks of treatment; OS at week 8
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.